## Edgar Filing: BELANOFF JOSEPH K - Form 4

BELANOF	F JOSEPH K									
Form 4										
December 1										
FORM	A 4 UNITE	D STATES					NGE CO	MMISSION	OMB	9ROVAL 3235-0287
Check t	his box		VV á	asningtoi	n, D.C. 20	549			Number: Expires:	January 31,
if no lor subject Section Form 4 Form 5	to SIAII 16. or	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES								
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and BELANOF						. Relationship of Reporting Person(s) to ssuer (Check all applicable)				
INCORPO	<sup>(First)</sup> CEPT THERAP RATED, 149 IWEALTH DR			'Day/Year)	Transaction		_	_X Director _X Officer (give t elow) Chief Ez		Owner r (specify er
	Filed(Month/Day/Year) A					5. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting				
MENLO P	ARK, CA 9402	5					P	erson	ne than one Rep	Johning
(City)	(State)	(Zip)	Tal	ble I - Non	-Derivative	Securi	ities Acqui	red, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	te 2A. Deem Execution any (Month/Da	Date, if	3. Transactic Code (Instr. 8)		f (D)		Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	
Common Stock	12/12/2018			М	217,115	А	\$ 1.19	2,381,310	D	
Common Stock	12/12/2018			S	217,115	D	\$ 19.0061	2,164,195	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control

### Edgar Filing: BELANOFF JOSEPH K - Form 4

#### number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of tiorDerivative Securities ) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.19	12/12/2018		М	2	17,115	(2)	02/07/2028	Common Stock	217,115

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
1			10% Owner	Officer	Other		
BELANOFF JOSEPH K C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025				Chief Executive Officer			
Signatures							
/s/ Joseph K. Belanoff	12/14/2018						
**Signature of	Date						

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from \$18.75 to \$19.48 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
- (2) Fully exercisable.

Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.